Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 5/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8845966 | 0.91 | CFD (0.46) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL8845961 | 0.91 | PTGER1 (0.45) | PTGER1PTGER4PTGER3PTGER2CYP26A1 | |
| SCHEMBL8846089 | 0.87 | RXRA (0.49) | PTGER1RXRARXRBRXRGFOLH1 | |
| SCHEMBL8846040 | 0.82 | PTGER1 (0.64) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL8846127 | 0.82 | CFD (0.53) | PTGER1PTGER4PTGER3PTGER2CYP26A1 | |
| SCHEMBL8845949 | 0.81 | CFD (0.43) | PTGER1PTGER4PTGER3PTGER2CYP26A1 | |
| SCHEMBL8072478 | 0.80 | RARG (0.52) | CYP26A1CYP26B1FFAR1RXRARARA | |
| SCHEMBL8845946 | 0.79 | PDE4A (0.50) | PTGER1PTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL8846106 | 0.79 | LTB4R (0.56) | PTGER1PTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL8845951 | 0.78 | RXRA (0.47) | PTGER1CYP26A1CYP26B1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0664282-B1 | Biaryl phospholipase A2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 1997-10-22 | — | — | EP | claimed |
| EP-0664282-A1 | Biaryl phospholipase A2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-26 | — | — | EP | claimed |
| US-5391817-A | Antiinflammatory agents | BRISTOL-MYERS SQUIBB (US) | 1995-02-21 | — | — | US | claimed |
| US-8772327-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| EP-2272832-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| US-6376546-B1 | ANTIALLERGENS | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2002-04-23 | — | — | US | disclosed |
| EP-1024130-A1 | BIPHENYL-5-ALKANOIC ACID DERIVATIVES AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-08-02 | — | — | EP | disclosed |
| EP-0664282-B1 | Biaryl phospholipase A2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 1997-10-22 | — | — | EP | disclosed |
| EP-0664282-A1 | Biaryl phospholipase A2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5391817-A | Antiinflammatory agents | BRISTOL-MYERS SQUIBB (US) | 1995-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | PTGER1 39/4885PTGER4 22/4885PTGER3 62/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | PTGER1 1/4885PTGER4 27/4885PTGER3 11/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | PTGER1 39/4885PTGER4 22/4885PTGER3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.